These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9339203)

  • 1. [Tumor suppressor p53 gene: a potential target for cancer therapy?].
    Soussi T
    Bull Cancer; 1997 Jul; 84(7):753-6. PubMed ID: 9339203
    [No Abstract]   [Full Text] [Related]  

  • 2. [P53 mutations, asset or disadvantage for cancer chemotherapy].
    Jacquemin-Sablon A
    Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and response to chemotherapy and radiotherapy.
    Ruley HE
    Important Adv Oncol; 1996; ():37-56. PubMed ID: 8791127
    [No Abstract]   [Full Text] [Related]  

  • 4. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J; Cho JY; Kim JH; Jung KC; Yun CO
    Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.
    Ganly I; Kim YT; Hann B; Balmain A; Brown R
    Gene Ther; 2001 Mar; 8(5):369-75. PubMed ID: 11313813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
    Naumann U; Kügler S; Wolburg H; Wick W; Rascher G; Schulz JB; Conseiller E; Bähr M; Weller M
    Cancer Res; 2001 Aug; 61(15):5833-42. PubMed ID: 11479223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
    Petty RD
    Clin Oncol (R Coll Radiol); 1996; 8(3):186-9. PubMed ID: 8814375
    [No Abstract]   [Full Text] [Related]  

  • 10. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53 tumour suppressor gene.
    Steele RJ; Thompson AM; Hall PA; Lane DP
    Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
    Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
    Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
    Rizk NP; Chang MY; El Kouri C; Seth P; Kaiser LR; Albelda SM; Amin KM
    Cancer Gene Ther; 1999; 6(4):291-301. PubMed ID: 10419047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate.
    Kunisaki R; Ikawa S; Maeda T; Nakazaki Y; Kurita R; Harata M; Shutoh Y; Bai YS; Soda Y; Tanabe T; Dohi T; Kato R; Ikawa Y; Asano S; Tani K
    J Gene Med; 2006 Sep; 8(9):1121-30. PubMed ID: 16832836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance.
    Lønning PE
    Trends Mol Med; 2004 Mar; 10(3):113-8. PubMed ID: 15102353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [p53 as a molecular target for cancer therapy].
    Ishioka C; Osada M; Gamo M; Kanamaru R
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
    Mendoza-Rodríguez CA; Cerbón MA
    Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E1B-deleted adenovirus replicates in p53-deficient lung cancer cells due to the absence of apoptosis.
    Harada N; Maniwa Y; Yoshimura M; Nagata M; Hamada H; Yokono K; Okita Y
    Oncol Rep; 2005 Nov; 14(5):1155-63. PubMed ID: 16211279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 as a potential target in cancer therapy.
    Ozturk M; Ponchel F; Puisieux A
    Bone Marrow Transplant; 1992; 9 Suppl 1():164-70. PubMed ID: 1504661
    [No Abstract]   [Full Text] [Related]  

  • 20. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells.
    Maheswaran S; Englert C; Lee SB; Ezzel RM; Settleman J; Haber DA
    Oncogene; 1998 Apr; 16(16):2041-50. PubMed ID: 9572485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.